Trial Profile
ERtugliflozin triAl in DIabetes With Preserved or Reduced ejeCtion FrAcTion mEchanistic Evaluation in Heart Failure: "ERADICATE-HF"
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 May 2023
Price :
$35
*
At a glance
- Drugs Ertugliflozin (Primary)
- Indications Heart failure; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms ERADICATE-HF
- 15 May 2023 Status changed from not yet recruiting to completed.
- 01 May 2018 Planned initiation date changed from 1 Mar 2018 to 7 May 2018.
- 02 Feb 2018 New trial record